Establishment Labs Holdings Inc. filings document regulatory disclosures for a British Virgin Islands medical technology issuer listed on Nasdaq. Its Form 8-K reports cover operating results and financial condition, preliminary financial information, Regulation FD presentation materials, credit-agreement amendments, senior secured term-loan obligations, and other material definitive agreements.
The company’s proxy materials disclose board matters, executive compensation, equity awards, shareholder voting items, and governance practices. Together, the filings describe the Motiva-focused breast aesthetics and reconstruction business, capital structure, debt arrangements, forward-looking-statement disclosures, and recurring corporate reporting obligations.
ESTABLISHMENT LABS HOLDINGS INC. saw affiliated investment funds managed by JW Asset Management report open-market sales of its Common Shares. On May 20, 2026, a total of 3,580 shares were sold at $70.56 per share, and on May 21, 2026, 16,999 shares were sold at $71.40 per share. Footnotes state these transactions reflect 15,350 shares sold by JW Partners, LP and 5,229 shares sold by JW Opportunities Fund, LLC. After these trades, the reporting group collectively reports holding 2,981,115 Common Shares indirectly. The Advisor, the General Partner and Jason G. Wild each disclaim beneficial ownership except to the extent of any indirect pecuniary interest.
Establishment Labs Holdings Inc. held its Annual Meeting of Shareholders on May 22, 2026. Shareholders elected six directors to serve until the 2027 annual meeting, including Filippo “Peter” Caldini, who received 20,009,113 votes for and 21,173 against, and Edward Schutter, who received 20,001,165 votes for and 29,105 against.
Shareholders also approved, on an advisory basis, the compensation of the company’s named executive officers with 19,999,556 votes for and 30,543 against, with 3,063,262 broker non-votes. In addition, they ratified the appointment of CBIZ, CPAs P.C. as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 22,686,230 votes for and 405,748 against.
Establishment Labs Holdings Inc. ownership table shows 1,578,119 common shares beneficially owned, representing 5.38% of the class as reported. The filing lists voting and dispositive powers across affiliated filers led by Brown Advisory Inc., with details of sole and shared voting/dispositive counts.
The schedule states the shares are held by investment companies and managed accounts of Brown Advisory subsidiaries and that Brown Advisory Inc. filed on behalf of those subsidiaries pursuant to the cited parent/subsidiary classification.
ESTABLISHMENT LABS HOLDINGS INC. director Juan Jose Chacon Quiros reported open-market sales of common shares executed on May 6, 2026 through entity Sariel Group Ltd, which holds the shares. The filing shows a total of 105,000 shares sold in two tranches under a pre-established Rule 10b5-1 trading plan, concluding that plan after all its shares were sold. Following these transactions, he continues to hold 45,193 common shares directly and 927,504 common shares indirectly through Sariel Group Ltd.
Establishment Labs Holdings Inc. reported first-quarter 2026 results showing strong growth but continued losses. Revenue rose to $59.9 million, up from $41.4 million a year earlier, driven by broader sales of Motiva Implants, including the United States.
Gross profit increased to $42.3 million, while the operating loss narrowed to $6.5 million and net loss improved to $13.4 million, or $0.45 per share. Cash and cash equivalents were $68.1 million, with net cash used in operating activities reduced to $4.3 million from $20.7 million. The balance sheet shows total assets of $351.0 million and shareholders’ equity of $14.8 million, alongside $246.4 million of Oaktree term debt and related obligations.
ESTABLISHMENT LABS HOLDINGS INC. had 60,000 Common Shares sold in an open-market transaction on May 6, 2026, by investment entities associated with JW Asset Management. The sale occurred at an average price of $75.625 per share and was executed indirectly through JW Partners, LP and JW Opportunities Fund, LLC.
After this sale, the reporting group collectively held 3,001,694 Common Shares indirectly. JW Asset Management, LLC, JW GP, LLC and Jason G. Wild each disclaim beneficial ownership of these securities except to the extent of any indirect pecuniary interest.
Establishment Labs Holdings Inc. reported strong first-quarter 2026 results with revenue of $59.9 million, up 44.7% from the same period in 2025, driven by Motiva sales and minimally invasive products. Gross margin improved to 70.7%, and the company delivered its third consecutive quarter of positive adjusted EBITDA.
Net loss narrowed to $13.4 million from $20.7 million a year earlier, while cash used in the quarter fell to $7.5 million and cash on hand was $68.1 million as of March 31, 2026. Management raised full-year 2026 revenue guidance to a range of $266.5 million to $268.5 million and now expects the minimally invasive business to exceed $35 million, with positive adjusted EBITDA every quarter and free cash flow positivity in the second half of 2026.
ESTABLISHMENT LABS HOLDINGS INC. director Juan Jose Chacon Quiros reported open-market sales totaling 75,000 Common Shares, executed indirectly through Sariel Group Ltd, an entity in which he has a pecuniary interest and over whose shares he has voting and dispositive power.
The sales occurred on May 1 and May 4, 2026 at weighted average prices between about $70 and $71 per share, under a Rule 10b5-1 trading plan. Following these transactions, Sariel Group Ltd holds 1,032,504 Common Shares indirectly attributed to him, and he also holds 45,193 Common Shares directly.
Establishment Labs Holdings Inc. entered into an amended credit agreement with Oaktree-affiliated lenders providing term loans of up to $300,000,000. The facility includes a $265,000,000 Tranche E funded at closing and a Tranche F of up to $35,000,000 available upon mutual consent.
About $259,000,000 from Tranche E will repay all obligations under the prior credit agreement and related costs, with remaining proceeds for working capital and general corporate purposes. The term loans bear interest at 8.75% per annum with partial payment-in-kind options in the first year, mature on April 30, 2031, carry a 1% original issue discount and a 1% exit fee on repayments, and are subject to prepayment premiums in the first three years.
ESTABLISHMENT LABS HOLDINGS INC. director Juan Jose Chacon Quiros reported indirect open-market sales totaling 75,000 common shares over April 23–27. The trades, executed at prices in the mid‑$60s per share, were carried out under a disclosed Rule 10b5-1 trading plan.
The shares were sold by Sariel Group Ltd., over which Chacon Quiros has voting and dispositive power, while disclaiming beneficial ownership beyond his pecuniary interest. After these sales, indirect holdings stood at 1,107,504 common shares, and a separate direct position was 45,193 common shares as of April 23.